Geranic acid is a comparatively niche monoterpenoid acid in the AromaForge archive, with a much thinner evidence base than better-known rose-family alcohols and esters such as geraniol or geranyl acetate. Live sources strongly support its identity, stereochemical distinction from neric acid, and occurrence in the archive's jade wood profile, while biological evidence is scattered across tyrosinase, microbial metabolism, and engineered-plant or formulation research rather than mainstream fragrance toxicology or clinical literature. Public safety coverage does exist through a RIFM assessment record, but the searchable abstract itself is not publicly exposed. For AromaForge, geranic acid is best handled as a chemistry-first constituent with a few mechanistic or preclinical signals and explicit evidence gaps.
Chemical identity and composition
NIST and PubChem identify geranic acid as the (2E) unsaturated monoterpenoid acid C10H16O2 and distinguish it from the double-bond isomer neric acid. Archive occurrence is currently sparse: the live oil corpus only clearly retains it in jade wood, where it behaves more like a distinctive supporting acid marker than a broadly distributed perfume staple.
Aroma and practical use
- Use the recorded green, sweet, floral, geranium-like, acidic-waxy descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2008 Journal of Agricultural and Food Chemistry paper identified geranic acid from lemongrass as a tyrosinase inhibitor.
The PubMed abstract states that assay-guided purification from lemongrass yielded geranic acid as one of the active tyrosinase-inhibiting compounds.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A maize metabolic-engineering study pursued geranic acid accumulation to improve fungal resistance, but reported that the strategy was compromised by novel glycosylation patterns.
The abstract is useful mainly as evidence that geranic acid has been investigated as a bioactive plant metabolite, while also underscoring that functional performance was limited in the engineered system.
This experimental finding does not establish benefit, dose or safety in people using this blend.
Anaerobic monoterpene-metabolism work identified geranic acid formation as an initial reaction during degradation by denitrifying bacteria.
The PMC article reports accumulation of geranic acid under defined conditions and uses it to map early monoterpene transformation chemistry.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
A RIFM fragrance ingredient safety assessment for geranic acid exists in the indexed literature, but the publicly searchable record available in this pass exposed citation metadata rather than an abstract or full open PDF.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct public citation is attached to this entry.
Because the public safety record was not fully readable in this pass, this constituent should be treated more conservatively than better-documented fragrance materials.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Current public evidence does not justify wellness or skin-benefit claims for geranic acid in aroma use contexts.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
tyrosinase inhibition
A PubMed-indexed lemongrass paper identified geranic acid as a tyrosinase inhibitor, supporting a plausible enzyme-target mechanism in vitro.
This experimental finding does not establish benefit, dose or safety in people using this blend.
intermediate in microbial monoterpene oxidation pathways
Microbiology papers describe geranic acid as an oxidation product or metabolic intermediate during monoterpene degradation and transformation, which is mechanistically useful for chemistry context even if not a consumer-facing benefit mechanism.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (8)
- Public isolated safety data for geranic acid were thin in this pass because the indexed RIFM record exposed citation metadata but not a readable abstract or open full text.
- The archive currently has only one clearly retained oil-occurrence example for geranic acid.
- No human clinical evidence relevant to aromatic use was verified.
- Much of the accessible geranic acid literature is biochemical, metabolic-engineering, or formulation adjacent rather than classic fragrance toxicology or constituent pharmacology.
- 2026-07-13 verification pass: re-attempted retrieval of the RIFM fragrance ingredient safety assessment (CAS 459-80-3, Food Chem Toxicol 2018;122:S68-S74) via PubMed (blocked by bot-check) and Fraunhofer repository (metadata only, no abstract/full text exposed); no specific dermal_limit_pct, NESIL, or IFRA category could be confirmed, so the prior dermal_limit_pct (5) placeholder has been corrected to null pending full-text access.
- 2026-07-13 second-pass retry: attempted direct full-text access to the RIFM PDF at fragrancematerialsafetyresource.elsevier.com/sites/default/files/459-80-3.pdf (returned empty/no content) and to the ResearchGate record for the same assessment (returned empty/no content); also searched for a published NESIL value for geranic acid specifically and found only the unrelated geraniol NESIL (11000 ug/cm2). No numeric dermal limit, NESIL, sensitization, or phototoxicity determination for geranic acid itself was obtained. dermal_limit_pct, sensitizing, and phototoxic remain null/false-unverified pending accessible full text.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.